Bio-Thera will obtain an upfront payment of $21m and could earn up to $143.5m in development and commercial milestones.

Accord BioPharma Inc., the U.S. specialty division of Intas Pharmaceuticals Ltd., has reached an exclusive commercialization and license agreement with Bio-Thera Solutions for BAT2506, a biosimilar ...

Serplulimab is the world’s first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC; Serplulimab is the first and only anti-PD-1 mAb approved in th ...

London-headquartered Accord is one of the largest suppliers of chemotherapy products in Europe and is a wholly-owned subsidiary of India's Intas Pharma, which has annual revenues of around $3.4 ...

Stomatologicals and blood-related therapies recorded the highest number of new products ... Sun Pharma maintained market leadership, while Emcure and Torrent advanced to 10th and 16th positions, ...

New Delhi: Intas Pharmaceuticals has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to conduct the Phase I clinical trial ...

The hospital lobby is petitioning President Donald Trump to grant carve-outs for medical devices and pharmaceutical products to the tariffs his administration has enacted, or may soon enact ...

February is Heart Month, a time to focus on the health and well-being of Ontarians. In recognition of this, and in advance of the upcoming provincial election, we are calling on all political parties ...

Norlase today announced the appointment of Jacob Philipsen, CEO of Advalight and co-founder of Norlase, as the new Chairman of the Board of Directors. Dr. Philipsen served as a board member prior to ...

D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...

The past two years have been punishing for the biotech and pharma space. As Wall Street chased the artificial-intelligence boom, drugmakers were left behind, with pharma stocks trading at a ...